MacroGenics, Inc. (MGNX)
2.04
-0.13
(-5.99%)
USD |
NASDAQ |
Nov 17, 16:00
2.04
0.00 (0.00%)
After-Hours: 20:00
MacroGenics Enterprise Value : 42.16M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 42.16M |
| November 13, 2026 | 44.08M |
| November 12, 2026 | 49.83M |
| November 11, 2026 | 51.74M |
| November 10, 2026 | 58.13M |
| November 09, 2026 | 53.02M |
| November 06, 2026 | 52.38M |
| November 05, 2026 | 45.36M |
| November 04, 2026 | 51.11M |
| November 03, 2026 | 52.38M |
| November 02, 2026 | 52.38M |
| October 30, 2026 | 56.85M |
| October 29, 2026 | 55.58M |
| October 28, 2026 | 61.33M |
| October 27, 2026 | 59.41M |
| October 26, 2026 | 43.44M |
| October 23, 2026 | 47.27M |
| October 22, 2026 | 135.42M |
| October 21, 2026 | 132.87M |
| October 20, 2026 | 126.48M |
| October 19, 2026 | 116.26M |
| October 16, 2026 | 111.15M |
| October 15, 2026 | 118.81M |
| October 14, 2026 | 114.98M |
| October 13, 2026 | 122.01M |
| Date | Value |
|---|---|
| October 12, 2026 | 141.17M |
| October 09, 2026 | 142.45M |
| October 08, 2026 | 130.31M |
| October 07, 2026 | 130.31M |
| October 06, 2026 | 136.06M |
| October 05, 2026 | 144.36M |
| October 02, 2026 | 132.23M |
| October 01, 2026 | 133.51M |
| September 30, 2026 | 150.11M |
| September 29, 2026 | 264.89M |
| September 28, 2026 | 283.34M |
| September 25, 2026 | 262.98M |
| September 24, 2026 | 266.80M |
| September 23, 2026 | 266.80M |
| September 22, 2026 | 287.16M |
| September 21, 2026 | 287.16M |
| September 18, 2026 | 288.44M |
| September 17, 2026 | 287.80M |
| September 16, 2026 | 284.62M |
| September 15, 2026 | 282.07M |
| September 14, 2026 | 292.25M |
| September 11, 2026 | 279.52M |
| September 10, 2026 | 277.62M |
| September 09, 2026 | 286.53M |
| September 08, 2026 | 299.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.321B |
| Alnylam Pharmaceuticals, Inc. | 20.79B |
| Anika Therapeutics, Inc. | 154.24M |
| Savara, Inc. | 818.43M |
| Arrowhead Pharmaceuticals, Inc. | 6.454B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.48M |
| Revenue (Quarterly) | 18.67M |
| Total Expenses (Quarterly) | 40.14M |
| EPS Diluted (Quarterly) | -0.3369 |
| Gross Profit Margin (Quarterly) | 98.93% |
| Profit Margin (Quarterly) | -115.0% |
| Earnings Yield | -40.84% |
| Normalized Earnings Yield | -40.84 |